Cargando…
The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709822/ https://www.ncbi.nlm.nih.gov/pubmed/31686781 http://dx.doi.org/10.2147/DDDT.S166765 |
_version_ | 1783446248767881216 |
---|---|
author | Antza, Christina Nirantharakumar, Krishnarajah Doundoulakis, Ioannis Tahrani, Abd A Toulis, Konstantinos A |
author_facet | Antza, Christina Nirantharakumar, Krishnarajah Doundoulakis, Ioannis Tahrani, Abd A Toulis, Konstantinos A |
author_sort | Antza, Christina |
collection | PubMed |
description | Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and importantly the observed benefits in cardiovascular disease reduction. Their major drawback is the subcutaneous route of administration, constituting a barrier to adoption and reason for treatment discontinuation. Thus, the development of an oral GLP1-RA agent would promote medication adherence and quality of life, further consolidating its beneficial effects in real-life clinical practice. However, this task is hampered by suboptimal gastrointestinal protein absorption. Yet, the introduction of oral semaglutide, a modified form of semaglutide with the addition of a carrier sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, may have provided a safe and effective way to reach systemic circulation while other molecules are in development. Whether this molecule still has the impressive cardiovascular effects demonstrated with the use of its precursor remains to be explored. However, to date, its efficacy and safety have already been showcased in a randomized trial. More research is warranted in order to further consolidate these findings across different type 2 diabetes mellitus (T2DM) subpopulations, and adequately powered studies with a longer follow-up that would allow the exploration of microvascular and macrovascular complications are needed. Finally, studies comparing oral semaglutide and similar molecules with other currently established antidiabetic agents to evaluate the relative efficacy, the cost-effectiveness and further understand its place in T2DM therapeutic algorithm are needed. This review focuses on the development of oral GLP1-RA agents and summarizes the challenges, milestones and expected benefits associated with a successful introduction. |
format | Online Article Text |
id | pubmed-6709822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67098222019-11-04 The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date Antza, Christina Nirantharakumar, Krishnarajah Doundoulakis, Ioannis Tahrani, Abd A Toulis, Konstantinos A Drug Des Devel Ther Review Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and importantly the observed benefits in cardiovascular disease reduction. Their major drawback is the subcutaneous route of administration, constituting a barrier to adoption and reason for treatment discontinuation. Thus, the development of an oral GLP1-RA agent would promote medication adherence and quality of life, further consolidating its beneficial effects in real-life clinical practice. However, this task is hampered by suboptimal gastrointestinal protein absorption. Yet, the introduction of oral semaglutide, a modified form of semaglutide with the addition of a carrier sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, may have provided a safe and effective way to reach systemic circulation while other molecules are in development. Whether this molecule still has the impressive cardiovascular effects demonstrated with the use of its precursor remains to be explored. However, to date, its efficacy and safety have already been showcased in a randomized trial. More research is warranted in order to further consolidate these findings across different type 2 diabetes mellitus (T2DM) subpopulations, and adequately powered studies with a longer follow-up that would allow the exploration of microvascular and macrovascular complications are needed. Finally, studies comparing oral semaglutide and similar molecules with other currently established antidiabetic agents to evaluate the relative efficacy, the cost-effectiveness and further understand its place in T2DM therapeutic algorithm are needed. This review focuses on the development of oral GLP1-RA agents and summarizes the challenges, milestones and expected benefits associated with a successful introduction. Dove 2019-08-22 /pmc/articles/PMC6709822/ /pubmed/31686781 http://dx.doi.org/10.2147/DDDT.S166765 Text en © 2019 Antza et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Antza, Christina Nirantharakumar, Krishnarajah Doundoulakis, Ioannis Tahrani, Abd A Toulis, Konstantinos A The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title_full | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title_fullStr | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title_full_unstemmed | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title_short | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
title_sort | development of an oral glp-1 receptor agonist for the management of type 2 diabetes: evidence to date |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709822/ https://www.ncbi.nlm.nih.gov/pubmed/31686781 http://dx.doi.org/10.2147/DDDT.S166765 |
work_keys_str_mv | AT antzachristina thedevelopmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT nirantharakumarkrishnarajah thedevelopmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT doundoulakisioannis thedevelopmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT tahraniabda thedevelopmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT touliskonstantinosa thedevelopmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT antzachristina developmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT nirantharakumarkrishnarajah developmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT doundoulakisioannis developmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT tahraniabda developmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate AT touliskonstantinosa developmentofanoralglp1receptoragonistforthemanagementoftype2diabetesevidencetodate |